Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Opportunity to buy cheap shares?
Think this down move is exaggerated. Company growth will slow from the usual 25% to around 15%, yet it's currently being priced as if no growth.
One third of value in cash. 2.7x sales multiple. A larger competitor will be looking at GIMO for potential acquisition
http://lastfinancier.com/gigamons-gimo-weak-guidance-an-opportunity-to-scoop-shares-cheap/
Even though stock is down, Organovo has been adding value
CEO Murphy has delivered on KOLs and other set targets. The second half of 2014 should continue to present value adding catalysts.
http://lastfinancier.com/organovo-onvo-developing-3d-bioprinting-technology-amid-market-volatility/
EveryWare going down an inevitable path
http://lastfinancier.com/everyware-evry-bankruptcy/
Reward not worth the risk with this much surrounding uncertainty
http://lastfinancier.com/nq-mobile-uncertainty-warrant-investment/
The slide was imminent. Buying at levels above $40 and you have a good chance of being the greater fool. This is all hype
http://lastfinancier.com/gopro-gpro-ipo-good-exit-point-existing-shareholders-not-entry-new-investors/
This IPO is for insiders to cash out! Don't be buying this hype
http://lastfinancier.com/gopro-gpro-ipo-good-exit-point-existing-shareholders-not-entry-new-investors/
Insiders buying plus ESMO presentation coming up. Mack is good value here
http://www.conferencecalltranscripts.org/summary/?id=1066501
Sell xG on this news. Move today not justified
http://lastfinancier.com/xg-technology-xgti-rises-subcontract-us-army-sell/
Can the recent SSYS run carry on? Increasing number of short sellers could add fuel to the fire if rally continues
http://lastfinancier.com/summer-short-squeeze-3d-printing-stocks/
Short squeeze likely this summer?
http://lastfinancier.com/summer-short-squeeze-3d-printing-stocks/
Seeking alpha misinformed on ONVO's 10K.
This is what caused the drop couple weeks back http://seekingalpha.com/news/1797463-organovo-reports-fy-results
However, what Seeking Alpha had was wrong http://lastfinancier.com/summer-short-squeeze-3d-printing-stocks/
Up 7% so far today. Seems the market agrees that drop was over done. Great fundamentals at these levels
Pipeline is diverse and have about $5.30/share in cash. Trading $1 above that cash value. Value play IMO
http://lastfinancier.com/endocyte-ecyt-and-merrimack-mack-not-good-enough-for-big-pharma-but-good-enough-for-you/
Perspective investors should be keeping an eye on MACK with MM-398 FDA application coming up.
The drop from Sanofi news may be recovered by next week
http://lastfinancier.com/endocyte-ecyt-and-merrimack-mack-not-good-enough-for-big-pharma-but-good-enough-for-you/
2015 the year of profitability
http://lastfinancier.com/senomyx-snmx-health-movement-of-partner-pepsico-pep/
Irish address and promising pipeline make Alkermes an attractive buyout target.
http://lastfinancier.com/amarin-amrn-and-alkermes-alks-tax-inversion-targets/
How much value does Amarin's Irish address hold?
A company about 4x Amarin size looking to cut taxes paid could do so with a corporate inversion strategy. It's becoming the driver of some of these cross border M&A deals like the MDT and COV one today and the Pfizer & AstraZeneca rumors. Any chance Amarin could be a target?
http://lastfinancier.com/amarin-amrn-and-alkermes-alks-tax-inversion-targets/
$ICLD up on fluff. Short as fade is near
http://lastfinancier.com/intercloud-system-icld-rises-up-on-fluff-news/
ICLD up big today on fluff news
http://lastfinancier.com/intercloud-system-icld-rises-up-on-fluff-news/
InterCloud is up today on fluff news
http://lastfinancier.com/intercloud-system-icld-rises-up-on-fluff-news/
From an investment standpoint then, does OREX have more upside in the short term considering a 15% cut
http://lastfinancier.com/orexigen-orex-falls-on-fda-delay-weight-loss-drug/
If OREX hits low $5s I think its a no brainer
Is OREX a better investment than competitors Arena and Vivus after today's drop?
http://bit.ly/1odUf0p
Was today's 36% move an overreaction?
http://lastfinancier.com/receptos-rcpt-big-gains-phase-2-results-overreaction/
Does the Idenix deal suggest that Achillion is the next takeover target?
http://lastfinancier.com/impact-on-hcv-players-after-merck-acquired-idenix/
Is such a move really warranted?
We're seeing short term selling, but Gilead will have HCV market all to itself for years. What kind of impact should non-approved competition have?
http://lastfinancier.com/impact-on-hcv-players-after-merck-acquired-idenix/
Is such a move really warranted?
We're seeing a short squeeze, but does the Idenix deal suggest that Achillion is the next takeover target?
http://lastfinancier.com/impact-on-hcv-players-after-merck-acquired-idenix/
$ALQA isn't quite as exciting but company will get the job done
http://lastfinancier.com/niche-health-care-companies-alliqua-horizon/
Alliqua $ALQA movement should continue with company's acquisition strategy
http://lastfinancier.com/niche-health-care-companies-alliqua-horizon/
Alliqua is the definition of substance>style
http://lastfinancier.com/niche-health-care-companies-alliqua-horizon/
Can recent slide be considered profit taking?
This article suggests so and that GLUU is undervalued
http://lastfinancier.com/glassesoff-glu-mobile-remain-top-picks-in-mobile-tech/
Raised $5M which should be enough to fund development of app for Android and marketing.
Released article discussing future of GLSO operations
http://lastfinancier.com/glassesoff-glu-mobile-remain-top-picks-in-mobile-tech/
Dan has held true to his word with the partnerships. Company is in good hands
Impressive strike $4 option volume expiring in Feb 2014. Very bullish
Volume has picked up this week. Hope we can continue this trend
And another article. Good to see investing community pick up on Neptune's story. 2014 will be a good year
http://seekingalpha.com/article/1959481-professional-investor-explains-his-2-largest-healthcare-holdings?source=yahoo
Article doesn't seem to have the right effect. Nonetheless, I'm intrigued by the potential CRO opportunity the company is interested in pursuing
Volume has picked up in last couple weeks with the price surge. This is being done without the launch of the app. Good momentum ride here
More good news
I agree with you PSFlyer that ADXS is better suited as an investment rather than a trade. Price action with this company is irrational. Longer term however, you can't deny the potential.
Results from cervical cancer study showed good safety profile and further improvements. Survival up to 28% from 22% and this is the low dose. The higher dosing could & should make results even better in the future. Add this to the list of positive advancements made in the last few months. Price is lagging